Clinical research progress and data on besetifan in the treatment of renal cancer

Belzutifan is a HIF-2α inhibitor that has received widespread attention in the treatment of clear cell renal cell carcinoma (ccRCC) in recent years. Unlike traditional targeted therapy, which mainly inhibits angiogenesis, bestivan directly acts on the hypoxia response pathway of tumors, and its target HIF-2α is one of the core factors driving tumor development in clear cell renal cancer. Because of this, it is considered a breakthrough new targeted drug, especially suitable for patients whose disease is still progressing after failure of previous multiple lines of treatment.

In clinical studies against advanced clear cell renal cell carcinoma, bezutivan showed promising anti-tumor activity. Especially in patients who have received treatments including PD-(L)1 immunotherapy and multiple VEGF pathway inhibitors, the drug still demonstrates the ability to delay disease progression and maintain tumor stability. More importantly, compared with traditional treatment methods, the drug is milder in controlling side effects. Especially for patients who have tolerated multiple drugs, besettivan has become an important back-line treatment supplement. Although the research results do not show absolute "superiority", their disease control rate is at least the same as that of existing control treatments, and even shows better clinical benefits in certain groups of people.

In addition, data from studies of besetifan in patients with renal cancer associated withVHL syndrome are also encouraging. Such patients often develop recurrent tumors in multiple sites and systems due to inherited VHL mutations, but there has been no clear targeted therapy in the past. In one study, although there was no control group, besotivan showed obvious advantages in reducing tumor volume and tumor burden, and some patients even achieved lesion regression. Although the sample size of this study is limited, it is a significant advance for this rare disease population.

Reference materials:https://www.welireg.com/